文献速递临床试验与 GCP流行病学与生物统计

口服阿奇霉素预防印度中低收入社区高危孕妇早产:pPAZI试验方案

Efficacy of oral azithromycin in pregnant women living in low-middle income neighborhoods with high risk of reproductive tract infections to prevent preterm birth: study protocol of an individually randomized trial (pPAZI trial).
PubMed 文献 · Trials · 2026-04-25

该方案拟在印度中低收入社区开展个体随机试验,纳入有生殖道感染高风险的孕妇,比较孕20–24周和28–32周口服阿奇霉素(每次1 g/日,连用2日)与对照(钙500 g/日,连用2日)对早产及其他小脆弱儿出生的预防效果,并随访母婴至产后2个月评估新生儿败血症、产妇产褥热或败血症、抗生素使用及表型大环内酯耐药累积发生率。

要点

  • 在印度中低收入社区,约半数生殖道感染常无症状或未报告,且与早产相关。
  • 阿奇霉素干预组于孕20–24周和28–32周各口服1 g/日连用2日,对照为钙500 g/日连用2日。
  • 主要结局为早产及其他小脆弱儿出生,随访至产后2个月评估母婴感染与耐药。

核心结论

  • 该方案将评估在印度非疟疾全流行区,孕期两疗程口服阿奇霉素能否预防高危生殖道感染孕妇的早产。

研究设计与样本

  • 个体随机试验,在印度中低收入社区纳入有生殖道感染高风险的孕妇。
  • 干预组于孕20–24周和28–32周口服阿奇霉素,每次1 g/日连用2日;对照为钙500 g/日连用2日。
  • 干预实施与结局评估由独立团队分别完成,母婴随访至产后2个月。

关键数值与推荐

  • 主要结局为早产及其他小脆弱儿出生。
  • 次要结局包括新生儿败血症、产妇产褥热或败血症、出生后2个月内抗生素使用及表型大环内酯耐药累积发生率。
  • 非洲试验提示孕期口服阿奇霉素在疟疾全流行区可大幅减少早产,但在南亚非全流行区效果尚不明确。

临床怎么用

  • 若结果有益,可为印度等高危人群中孕期阿奇霉素预防早产的政策讨论提供依据。
  • 研究将同步评估儿童生长、总体抗生素使用及抗菌药物耐药相关担忧。

局限性

  • 原文为试验方案,尚未报告干预效果数据。
  • 非洲疟疾全流行区证据能否外推至南亚非全流行区尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: India contributes to around one-fifth of all preterm births globally. Reproductive tract infections (RTIs), colonization of fetal membranes, and associated maternal inflammatory immune response are recognized as a major trigger associated with preterm birth. Azithromycin is a broad-spectrum macrolide antibiotic with anti-inflammatory properties and is commonly used for symptomatic reproductive tract infections. Evidence from African trials suggests that oral azithromycin in the antenatal period can substantially reduce preterm births in malaria holoendemic settings (where all pregnant women receive antimalarials as standard). It is unclear whether the intervention works in South Asian settings where malaria is not holoendemic. METHODS: Using an individually randomized trial design, our primary study objective is to evaluate whether two doses of oral azithromycin (each dose 1 g/day for two consecutive days) compared to control (calcium 500 g/day for two consecutive days) during the antenatal period, i.e., at 20-24 weeks and at 28-32 weeks of gestation, in Indian women with high risk of reproductive tract infections can substantially prevent preterm birth and birth of other small vulnerable infants. The live newborns and their mothers will be followed up till 2 months after birth to estimate the intervention effect on neonatal sepsis, puerperal pyrexia, or sepsis in the mothers, antibiotic use during the first 2 months of birth, and cumulative incidence of phenotypic macrolide resistance. Separate independent teams will conduct the intervention delivery and outcome assessment. DISCUSSION: In low-middle income neighborhoods in India, around half of the RTIs are often asymptomatic or unreported and contribute to preterm birth. Our approach involves screening pregnant women at risk of RTI and using azithromycin as a preventive treatment for preterm birth reduction in Indian settings. Additionally, the study will generate data on the intervention effect on child growth, overall antibiotic use, and any concern related to emerging antimicrobial resistance. If the results show a beneficial effect, they could inform policy discussions on the potential use of azithromycin as a preventative treatment for women at risk of RTIs to reduce preterm birth rates. TRIAL REGISTRATION: The trial has been registered prospectively in Clinical Trial Registry-India # CTRI/2024/10/075570, registered on 21 October 2024 https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=MTE0NzM1&Enc=&userName= .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Sinha B, Biswas R, Dhabhai N, et al. Efficacy of oral azithromycin in pregnant women living in low-middle income neighborhoods with high risk of reproductive tract infections to prevent preterm birth: study protocol of an individually randomized trial (pPAZI trial). Trials. 2026. PMID: 42032611. doi:10.1186/s13063-026-09745-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。